Bisphenol A (BPA) is one of the most detrimental pollutants in environment.  Inside the body, it is metabolized by the liver and hence triggers liver injury. Hydroxyapatite nanoparticles (HANPs) are selected in the current study as a safe way to adsorb the BPA and hence eliminate its toxic impacts in vivo.
HANPs formula was prepared by sol-gel techniques; characterization was confirmed by XRD, FTIR, morphology and thermal stability. In vivo study was conducted on Forty male rats which were equally divided into 4 groups. The negative control received 10%DMSO solution, HANPs group were ingested with 1g/ kg b.wt./day of HANPs, BPA group received 100 mg BPA/ kg b.w.t/ day, and the BPA+HANPs group were treated with 1 g HANPs/100mg BPA/ kg b.w.t/ day. The doses were given daily for six consecutive weeks orally. Blood samples were collected; serum was separated and used for determination of selected liver enzymes and lipid profile parameters.
ALT and AST levels were significantly increased with concomitant decrease in the total protein and albumin levels in the BPA group, compared to the control one. Cholesterol, Triglycerides and LDL-Cholesterol levels were also increased with concomitant decrease in the HDL-Cholesterol in the BPA group. On the other hand, BPA+HANPs group exhibited amelioration in the lipid profile parameters, as compared to the BPA one.
In conclusion, HANPs can be considered as a promising and effective biomaterial that can alleviate liver injury induced by exposure to the BPA pollutant.
Key words: Bisphenol A, health problems, liver enzymes, lipid profile